<?xml version='1.0' encoding='utf-8'?>
<document id="32000294"><sentence text="Protective effect of cilastatin against diclofenac-induced nephrotoxicity through interaction with diclofenac acyl glucuronide via organic anion transporters."><entity charOffset="21-31" id="DDI-PubMed.32000294.s1.e0" text="cilastatin" /><entity charOffset="40-50" id="DDI-PubMed.32000294.s1.e1" text="diclofenac" /><entity charOffset="99-126" id="DDI-PubMed.32000294.s1.e2" text="diclofenac acyl glucuronide" /><pair ddi="false" e1="DDI-PubMed.32000294.s1.e0" e2="DDI-PubMed.32000294.s1.e0" /><pair ddi="false" e1="DDI-PubMed.32000294.s1.e0" e2="DDI-PubMed.32000294.s1.e1" /><pair ddi="false" e1="DDI-PubMed.32000294.s1.e0" e2="DDI-PubMed.32000294.s1.e2" /><pair ddi="false" e1="DDI-PubMed.32000294.s1.e1" e2="DDI-PubMed.32000294.s1.e1" /><pair ddi="false" e1="DDI-PubMed.32000294.s1.e1" e2="DDI-PubMed.32000294.s1.e2" /></sentence><sentence text="Diclofenac is a widely used nonsteroidal anti-inflammatory drug"><entity charOffset="0-10" id="DDI-PubMed.32000294.s2.e0" text="Diclofenac" /></sentence><sentence text=" However, adverse effects in the kidney limit its clinical application" /><sentence text=" The present study was aimed to evaluate the potential effect of cilastatin on diclofenac-induced acute kidney injury and to clarify the potential roles of renal organic anion transporters (OATs) in the drug-drug interaction between cilastatin and diclofenac"><entity charOffset="65-75" id="DDI-PubMed.32000294.s4.e0" text="cilastatin" /><entity charOffset="79-89" id="DDI-PubMed.32000294.s4.e1" text="diclofenac" /><entity charOffset="233-243" id="DDI-PubMed.32000294.s4.e2" text="cilastatin" /><entity charOffset="248-258" id="DDI-PubMed.32000294.s4.e3" text="diclofenac" /><pair ddi="false" e1="DDI-PubMed.32000294.s4.e0" e2="DDI-PubMed.32000294.s4.e0" /><pair ddi="false" e1="DDI-PubMed.32000294.s4.e0" e2="DDI-PubMed.32000294.s4.e1" /><pair ddi="false" e1="DDI-PubMed.32000294.s4.e0" e2="DDI-PubMed.32000294.s4.e2" /><pair ddi="false" e1="DDI-PubMed.32000294.s4.e0" e2="DDI-PubMed.32000294.s4.e3" /><pair ddi="false" e1="DDI-PubMed.32000294.s4.e1" e2="DDI-PubMed.32000294.s4.e1" /><pair ddi="false" e1="DDI-PubMed.32000294.s4.e1" e2="DDI-PubMed.32000294.s4.e2" /><pair ddi="false" e1="DDI-PubMed.32000294.s4.e1" e2="DDI-PubMed.32000294.s4.e3" /><pair ddi="false" e1="DDI-PubMed.32000294.s4.e2" e2="DDI-PubMed.32000294.s4.e2" /><pair ddi="false" e1="DDI-PubMed.32000294.s4.e2" e2="DDI-PubMed.32000294.s4.e3" /></sentence><sentence text="" /><sentence text="The effect of cilastatin was evaluated in diclofenac-induced acute kidney injury in mice"><entity charOffset="14-24" id="DDI-PubMed.32000294.s6.e0" text="cilastatin" /><entity charOffset="42-52" id="DDI-PubMed.32000294.s6.e1" text="diclofenac" /><pair ddi="false" e1="DDI-PubMed.32000294.s6.e0" e2="DDI-PubMed.32000294.s6.e0" /><pair ddi="false" e1="DDI-PubMed.32000294.s6.e0" e2="DDI-PubMed.32000294.s6.e1" /></sentence><sentence text=" Human OAT1/3-transfected HEK293 cells and renal primary proximal tubule cells (RPTCs) were used to investigate OAT1/3-mediated transport and the cytotoxicity of diclofenac"><entity charOffset="162-172" id="DDI-PubMed.32000294.s7.e0" text="diclofenac" /></sentence><sentence text="" /><sentence text="Cilastatin treatment decreased the pathological changes, renal dysfunction and elevated renal levels of oxidation products, cytokine production and apoptosis induced by diclofenac in mice"><entity charOffset="0-10" id="DDI-PubMed.32000294.s9.e0" text="Cilastatin" /><entity charOffset="169-179" id="DDI-PubMed.32000294.s9.e1" text="diclofenac" /><pair ddi="false" e1="DDI-PubMed.32000294.s9.e0" e2="DDI-PubMed.32000294.s9.e0" /><pair ddi="false" e1="DDI-PubMed.32000294.s9.e0" e2="DDI-PubMed.32000294.s9.e1" /></sentence><sentence text=" Moreover, cilastatin increased the plasma concentration and decreased the renal distribution of diclofenac and its glucuronide metabolite, diclofenac acyl glucuronide (DLF-AG)"><entity charOffset="11-21" id="DDI-PubMed.32000294.s10.e0" text="cilastatin" /><entity charOffset="97-107" id="DDI-PubMed.32000294.s10.e1" text="diclofenac" /><entity charOffset="116-127" id="DDI-PubMed.32000294.s10.e2" text="glucuronide" /><entity charOffset="140-167" id="DDI-PubMed.32000294.s10.e3" text="diclofenac acyl glucuronide" /><entity charOffset="169-175" id="DDI-PubMed.32000294.s10.e4" text="DLF-AG" /><pair ddi="false" e1="DDI-PubMed.32000294.s10.e0" e2="DDI-PubMed.32000294.s10.e0" /><pair ddi="false" e1="DDI-PubMed.32000294.s10.e0" e2="DDI-PubMed.32000294.s10.e1" /><pair ddi="false" e1="DDI-PubMed.32000294.s10.e0" e2="DDI-PubMed.32000294.s10.e2" /><pair ddi="false" e1="DDI-PubMed.32000294.s10.e0" e2="DDI-PubMed.32000294.s10.e3" /><pair ddi="false" e1="DDI-PubMed.32000294.s10.e0" e2="DDI-PubMed.32000294.s10.e4" /><pair ddi="false" e1="DDI-PubMed.32000294.s10.e1" e2="DDI-PubMed.32000294.s10.e1" /><pair ddi="false" e1="DDI-PubMed.32000294.s10.e1" e2="DDI-PubMed.32000294.s10.e2" /><pair ddi="false" e1="DDI-PubMed.32000294.s10.e1" e2="DDI-PubMed.32000294.s10.e3" /><pair ddi="false" e1="DDI-PubMed.32000294.s10.e1" e2="DDI-PubMed.32000294.s10.e4" /><pair ddi="false" e1="DDI-PubMed.32000294.s10.e2" e2="DDI-PubMed.32000294.s10.e2" /><pair ddi="false" e1="DDI-PubMed.32000294.s10.e2" e2="DDI-PubMed.32000294.s10.e3" /><pair ddi="false" e1="DDI-PubMed.32000294.s10.e2" e2="DDI-PubMed.32000294.s10.e4" /><pair ddi="false" e1="DDI-PubMed.32000294.s10.e3" e2="DDI-PubMed.32000294.s10.e3" /><pair ddi="false" e1="DDI-PubMed.32000294.s10.e3" e2="DDI-PubMed.32000294.s10.e4" /></sentence><sentence text=" Similarly, cilastatin inhibited cytotoxicity and mitochondrial damage in RPTCs but did not change the intracellular accumulation of diclofenac"><entity charOffset="12-22" id="DDI-PubMed.32000294.s11.e0" text="cilastatin" /><entity charOffset="133-143" id="DDI-PubMed.32000294.s11.e1" text="diclofenac" /><pair ddi="false" e1="DDI-PubMed.32000294.s11.e0" e2="DDI-PubMed.32000294.s11.e0" /><pair ddi="false" e1="DDI-PubMed.32000294.s11.e0" e2="DDI-PubMed.32000294.s11.e1" /></sentence><sentence text=" DLF-AG but not diclofenac exhibited OAT-dependent cytotoxicity and was identified as an OAT1/3 substrate"><entity charOffset="16-26" id="DDI-PubMed.32000294.s12.e0" text="diclofenac" /></sentence><sentence text=" Cilastatin inhibited the intracellular accumulation and decreased the cytotoxicity of DLF-AG in RPTCs"><entity charOffset="1-11" id="DDI-PubMed.32000294.s13.e0" text="Cilastatin" /></sentence><sentence text="" /><sentence text="Cilastatin alleviated diclofenac-induced acute kidney injury in mice by restoring the redox balance, suppressing inflammation, and reducing apoptosis"><entity charOffset="0-10" id="DDI-PubMed.32000294.s15.e0" text="Cilastatin" /><entity charOffset="22-32" id="DDI-PubMed.32000294.s15.e1" text="diclofenac" /><pair ddi="false" e1="DDI-PubMed.32000294.s15.e0" e2="DDI-PubMed.32000294.s15.e0" /><pair ddi="false" e1="DDI-PubMed.32000294.s15.e0" e2="DDI-PubMed.32000294.s15.e1" /></sentence><sentence text=" Cilastatin inhibited OATs and decreased the renal distribution of diclofenac and DLF-AG, which further ameliorated the diclofenac-induced nephrotoxicity in mice"><entity charOffset="1-11" id="DDI-PubMed.32000294.s16.e0" text="Cilastatin" /><entity charOffset="67-77" id="DDI-PubMed.32000294.s16.e1" text="diclofenac" /><entity charOffset="82-88" id="DDI-PubMed.32000294.s16.e2" text="DLF-AG" /><entity charOffset="120-130" id="DDI-PubMed.32000294.s16.e3" text="diclofenac" /><pair ddi="false" e1="DDI-PubMed.32000294.s16.e0" e2="DDI-PubMed.32000294.s16.e0" /><pair ddi="false" e1="DDI-PubMed.32000294.s16.e0" e2="DDI-PubMed.32000294.s16.e1" /><pair ddi="false" e1="DDI-PubMed.32000294.s16.e0" e2="DDI-PubMed.32000294.s16.e2" /><pair ddi="false" e1="DDI-PubMed.32000294.s16.e0" e2="DDI-PubMed.32000294.s16.e3" /><pair ddi="false" e1="DDI-PubMed.32000294.s16.e1" e2="DDI-PubMed.32000294.s16.e1" /><pair ddi="false" e1="DDI-PubMed.32000294.s16.e1" e2="DDI-PubMed.32000294.s16.e2" /><pair ddi="false" e1="DDI-PubMed.32000294.s16.e1" e2="DDI-PubMed.32000294.s16.e3" /><pair ddi="false" e1="DDI-PubMed.32000294.s16.e2" e2="DDI-PubMed.32000294.s16.e2" /><pair ddi="false" e1="DDI-PubMed.32000294.s16.e2" e2="DDI-PubMed.32000294.s16.e3" /></sentence><sentence text=" Cilastatin can be potentially used in the clinic as a therapeutic agent to alleviate the adverse renal reaction to diclofenac"><entity charOffset="1-11" id="DDI-PubMed.32000294.s17.e0" text="Cilastatin" /><entity charOffset="116-126" id="DDI-PubMed.32000294.s17.e1" text="diclofenac" /><pair ddi="false" e1="DDI-PubMed.32000294.s17.e0" e2="DDI-PubMed.32000294.s17.e0" /><pair ddi="true" e1="DDI-PubMed.32000294.s17.e0" e2="DDI-PubMed.32000294.s17.e1" /></sentence><sentence text="" /></document>